Clinical Trials

Is Lantern Pharma's LP-300 a New Hope for NSCLC Patients?
Management & Regulatory Is Lantern Pharma's LP-300 a New Hope for NSCLC Patients?

Lantern Pharma's LP-300 signals a significant advancement in the fight against non-small cell lung cancer (NSCLC), particularly in never-smokers—a group seeing elevated incidence rates, notably in East Asia. This promising therapeutic option stands out as NSCLC treatments often overlook the u

Is ALLO-316 the Future of Kidney Cancer Treatment?
Research & Development Is ALLO-316 the Future of Kidney Cancer Treatment?

In the fight against kidney cancer, ALLO-316, created by Allogene Therapeutics, stands out in the vanguard with its CAR T-cell therapy. This breakthrough offers new hope against renal cell carcinoma (RCC), a type notorious for its defiance against traditional treatments. As ALLO-316 progresses

Algorae Leverages AI for Faster, Cheaper Drug Development
Research & Development Algorae Leverages AI for Faster, Cheaper Drug Development

Algorae Pharmaceuticals is revolutionizing the field of medicine with its state-of-the-art AI system, AlgoraeOS. By leveraging the extraordinary capabilities of Gadi, the mightiest supercomputer in the Southern Hemisphere, Algorae leads innovation in reimagining the use of existing medications.

Tokyo Lab Develops Safer 'Naked' mRNA Vaccine for COVID-19
Tech & Innovation Tokyo Lab Develops Safer 'Naked' mRNA Vaccine for COVID-19

A Breakthrough in Vaccine Delivery In a revolutionary shift from conventional immunization methods, scientists at Tokyo Medical and Dental University's Uchida Laboratory, along with various prestigious institutions, have created a "naked" mRNA vaccine for SARS-CoV-2. This

Can Gen AI Foster Ethical Progress in Biopharma?
Tech & Innovation Can Gen AI Foster Ethical Progress in Biopharma?

In a decisive move to safeguard financial stability and bolster public trust, the United States government has announced a significant intervention in the wake of the Silicon Valley Bank (SVB) failure. Unprecedented Access to Depositor Funds Starting on Monday, former clients of SVB are assured

Can Sutro Biopharma's $75M Offering Fuel Its Cancer Fight?
Management & Regulatory Can Sutro Biopharma's $75M Offering Fuel Its Cancer Fight?

To escalate the war on cancer, Sutro Biopharma has launched a public offering with the goal of raising $75 million. These proceeds are set to bolster Sutro's efforts in creating cutting-edge antibody-drug conjugates (ADCs), which stand at the forefront of its cancer treatment research. By

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later